7733 Share Price Performance
JP¥0
-1800.50 (-100.00%)
Price JP¥0
Fair ValueJP¥1,819.23
Share Pricen/a
Analysis Article • May 19
Olympus Corporation Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
7733 Community Narratives
AN
Fair Value
·Fair Value JP¥1.82k 2.4% undervalued intrinsic discount
7733: Market Will Weigh Product Recall Against Modest Guidance Revision Risk
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value JP¥2.21k 19.8% undervalued intrinsic discount
Digital And Robotic Endoscopy Will Serve A Growing Aging Market
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value JP¥1.5k 18.4% overvalued intrinsic discount
Austerity Policies And FDA Alerts Will Trigger Price Erosion
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Digital And Robotic Endoscopy Will Serve A Growing Aging Market
Olympus bets on smarter, more digital endoscopy and new surgical robotics to ride the growing demand for less invasive procedures as populations age. But ongoing regulator scrutiny, tougher local competition, and fast-moving medical tech shifts could slow its comeback if execution slips.Read more
AN
JP¥2.21k
19.8% undervalued intrinsic discount
Fair Value
Revenue
5.69% p.a.
Profit Margin
11.24%
Future PE
19.93x
Price in 2029
JP¥2.61k
Austerity Policies And FDA Alerts Will Trigger Price Erosion
Key Takeaways Shifting healthcare policies and increased regulatory scrutiny are squeezing Olympus' revenue streams, profitability, and escalating compliance and legal risks. Heavy dependence on core endoscopy and resistance to industry trends expose Olympus to market disruptions, price erosion, and long-term earnings volatility.Read more
AN
JP¥1.5k
18.4% overvalued intrinsic discount
Fair Value
Revenue
3.3% p.a.
Profit Margin
11.04%
Future PE
15.26x
Price in 2029
JP¥1.79k
7733: Market Will Weigh Product Recall Against Modest Guidance Revision Risk
Key Takeaways Reorganization into customer-focused divisions and new product launches are set to improve efficiency, increase market penetration, and enhance revenue and margins. Local manufacturing in China and FDA clearance in the U.S. bolster market share, with initiatives like Project Elevate strengthening global medtech position.Read more
AN
JP¥1.82k
2.4% undervalued intrinsic discount
Fair Value
Revenue
3.91% p.a.
Profit Margin
10.92%
Future PE
18.3x
Price in 2029
JP¥2.16k
Trending Discussion
Recently Updated Narratives
AN
7733: Share Repurchases And Higher Dividends Will Support Future Upside Potential
Fair Value: JP¥2.21k 19.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
7733: Dividend And Margin Outlook Will Offset Product And Leadership Uncertainty
Fair Value: JP¥1.5k 18.4% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
7733: Future Returns Will Reflect Imaging Platform Adoption And Higher Dividend
Fair Value: JP¥1.82k 2.4% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Olympus Corporation Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 07, 2026
- 64.18
- 64.72%
- 6.75%
- 29.5%
About 7733
- Founded
- 1919
- Employees
- 29297
- CEO
- WebsiteView website
Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, “Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, surgical endoscopes, energy devices, ENT products, and gynecology products. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.
